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Introduction
The optimal choice of feeding for an HIV-exposed infant is complex 
in developing countries. The risks of transmission of HIV through 
breastfeeding must be balanced against the many known benefits of 
breastfeeding in reducing infant mortality and morbidity. The cost of 
replacement feeding is substantial and also needs to be considered. 
Regardless of feeding choices, the growth of infants born to HIV-
infected mothers is determined largely by whether the infant 
is infected with HIV. An overview by Isanaka et al1 of patterns of 
postnatal growth in HIV-infected and HIV-exposed infants reviewed 
all papers published between 1985 and the end of 2008. While 
infants who were shown to be infected with HIV had poorer growth 
than those who were uninfected, those exposed to but uninfected 
with HIV had similar growth patterns to the reference population.1
For infants who are not breast fed from birth, a standard whey-
adapted starter formula that is close in many respects to human 
milk is usually recommended. For a number of years a biologically 
acidified starter formula has been commercially available in South 
Africa and has been used extensively. There is some evidence that 
intestinal infections are reduced in infants fed a biologically acidified 
formula.2 In a recent study, infants aged four to six months receiving 
the biologically acidified formula had the same number of diarrhoeal 
episodes, but they were less severe.3 A recent systematic review 
on biologically acidified formulas concluded that the existing data 
were too limited to allow firm conclusions regarding their potential 
benefits and safety, and recommended that further clinical trials 
should be performed.4
Biological acidification is usually achieved by introducing lactic 
acid-producing bacteria during the production process. Acidification 
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Objectives: The objectives of this study were to evaluate whether infants born to known HIV-positive mothers, but who were not themselves 
infected with HIV and who were fed a chemically acidified starter formula with prebiotics with or without nucleotides during their first six 
months, displayed growth rates equal to uninfected infants fed a chemically acidified starter formula without prebiotics or nucleotides.
Design: The design was a multi-centre, double-blinded randomised controlled trial. 
Setting: The study was carried out in four academic hospitals, three in Johannesburg and one in Cape Town, South Africa. 
Subjects and intervention: The subjects were newborn infants born to consenting HIV-positive women who had previously decided not to 
breast feed. The infants were randomised to receive one of three milk formulas. The intervention comprised chemically acidified formula 
without prebiotics or nucleotides, with prebiotics only, or with prebiotics and nucleotides.  
Outcome measures: The outcome measures were the growth parameters through the first six months of life.
Results: Of the 150 randomised infants, 50 did not complete the study and 16 (12.8% of those tested) were infected with HIV, leaving 84 
infants available for analysis. All three formulas were tolerated well, with no differences in growth parameters seen with the addition of 
prebiotics and nucleotides. The growth rates of the study infants up to the age of six months were very good, showing an increase in Z-scores 
from negative values at the time of enrolment in the first week after birth to around zero for length and > 0.5 for weight.
Conclusions: The three chemically acidified formulas were tolerated well and resulted in good growth over the first six months of life. No 
benefits were seen with the addition of prebiotics or nucleotides. The growth rates were similar to those found in previous studies of ours 
on biologically acidified formulas. The chemical acidification of infant formulas appears to be a realistic alternative to biological acidification 
should an acidified formula be required.
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can also be done chemically by adding L(+) lactic acid. This may 
have advantages in that production is simpler and cheaper and the 
precise amount of acidification can be controlled, leading to less 
variation from batch to batch. However, data on chemically acidified 
formulas in full-term infants have not been published.
Attempts to modulate the microbiota in formula-fed infants towards 
increased bifidobacteria counts have been achieved by adding either 
living bifidobacteria (probiotics) or substances enhancing the growth 
of lactic acid bacteria (prebiotics) to infant feeds. There is evidence 
that prebiotics may modulate the intestinal microbiota and the 
immune system in infants in the same way that human milk does.5 
Compared to control formulas, infants fed nucleotide-supplemented 
formula had an enhanced immune response to influenza and 
diphtheria, but not to tetanus or polio vaccinations,6 and also had 
fewer diarrhoeal episodes than those fed a non-supplemented 
formula.7,8
The main objective of this study was to evaluate the growth of 
infants, born to known HIV-positive mothers but who were not 
themselves infected with HIV, fed a chemically acidified starter 
formula with prebiotics with or without nucleotides during their 
first six months. If their growth was satisfactory, this would then 
allow the evaluation of the safety of the formulas. At the time this 
study commenced, we could find no published data on the use 
of chemically acidified milks for feeding term infants who were 
well. Since we also were doing studies on infants fed standard 
and biologically acidified formulas, comparison of growth rates of 
infants fed chemically acidified formulas with infants from these 
studies could be made. The secondary objectives were to assess the 
infants’ tolerance to chemically acidified formulas with and without 
prebiotics and nucleotides, to evaluate the frequency of episodes 
of morbidity (especially those related to infectious diseases), and to 
assess protein, biochemical and immunological status.
Methods
This study was a multi-centre, prospective, randomised, double-
blind controlled trial. It was carried out at the Johannesburg, Chris 
Hani Baragwanath, and Coronation Hospitals in Johannesburg, and 
at Groote Schuur Hospital in Cape Town, South Africa.  
All pregnant women attending the antenatal clinics of the hospitals 
are routinely offered testing for HIV. Those who test positive receive 
full post-test counselling, which includes discussion of the potential 
risks of breast- and formula feeding. During the study period, those 
who indicated that they did not plan to breast feed were then 
informed about the study. However, formal enrolment into the study 
only took place after delivery in order to ensure that all criteria 
for enrolment were met and that the mother still planned not to 
breast feed.
Inclusion criteria were healthy, normal, full-term infants (gestation 37 
to 42 weeks and birth weight 2 500 to 4 200 g) born to HIV-positive 
women who had elected not to breast feed. Infants with major 
congenital abnormalities and those with major illnesses requiring 
admission to an intensive care unit or hospital for more than three 
days after birth were excluded from the study. Subjects were also 
excluded if the mother planned to introduce feeds other than milk in 
the first four months of life, or if the mother planned to move out of 
the study area during the six-month study period. Recruitment into 
the study had to take place within one week of birth.
After enrolment, the infants were randomised into one of three 
feeding groups:
1. A chemically acidified whey-adapted starter formula (CAF)
2. A chemically acidified whey-adapted starter formula with 
prebiotics (CAFP)
3. A chemically acidified whey-adapted starter formula with 
prebiotics and nucleotides (CAFPN)
Acidification was achieved by the addition of L(+) lactic acid. 
The L(+) lactic acid constituted 2% of the powder formula and 
resulted in a pH of 4.7 when the product was reconstituted with 
tap water. The prebiotic was a blend of short-chain and long-
chain fructo-oligosaccharides (70:30) with a total of 2 g per litre 
when reconstituted to liquid form. The nucleotides were a blend 
of cytidine monophosphate, uridine monophosphate, adenosine 
monophosphate and guanosine monophosphate (approximately 
55:35:6:4 respectively). The formulas were similar to starter formulas 
in other respects, containing 67 kcal/100 ml, 1.5 g/100 ml of whey-
adapted protein and standard concentrations of electrolytes, trace 
elements and vitamins. All formulas contained polyunsaturated long-
chain fatty acids.
Assignment to the formula groups was performed by a computer-
generated randomisation table using Excel. Block randomisation 
was performed for each centre separately by the sponsor. Each 
centre received a set of sealed envelopes containing the subject 
number and treatment code. Once an infant was enrolled, the next 
envelope in the sequence was opened by the study personnel, and 
this indicated which of three colour-coded tins of milk the subject 
should receive. The investigators and the participants were blinded 
to the formula assignments, and the colour-coded tins ensured 
blinding as well as continuity of supply of the same formula to each 
infant. Details of the formula composition did not appear on the tins, 
in keeping with the double-blind design of the study.
At the time of enrolment, basic information regarding the pregnancy 
and delivery were recorded and the study personnel measured 
the infant’s weight, length and head circumference. Weight was 
measured to the nearest 10 g on an electronic scale, supine length 
was measured to the nearest 1 mm on a standard measuring 
board, and head circumference was measured to the nearest 1 
mm using a standard non-elastic plastic-coated measuring tape. 
The electronic scales were calibrated by the supply company and 
the same equipment was used at each hospital for all subsequent 
anthropometric measurements. The study personnel at each hospital 
were trained in measurement techniques and remained constant 
during the course of the study. Follow-up visits were scheduled for 
14, 28, 42, 56, 91, 119 and 182 days after enrolment. 
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After enrolment and randomisation to the study formula, the 
mothers received careful and detailed instructions regarding 
the safe preparation of formula and were advised according to 
standard guidelines regarding the usual amounts of milk required 
by their infants. However, the mothers were informed that their 
infants should be fed on demand, without restrictions regarding the 
frequency and volumes of feeds, and that additional water should not 
be given. The information on the safe preparation of formula was re-
enforced at each visit. Formal follow-up visits were as listed above, 
but, for practical reasons (size and weight of tins of formula that 
could be taken on public transport), mothers generally returned more 
frequently to collect tins of the powdered formula, typically every two 
weeks. The supply of the study formula was continued until the end 
of the study period, when the infants were at the age of six months. 
Infants were considered not to have complied with the study protocol 
if any of the following occurred:
1. The mother gave more than one bottle of another formula per 
week
2. The infant did not receive the study formula (due to the mother 
not being able to get supplies or illness in the infant) for more 
than seven consecutive days
3. Significant amounts (> 20 g) of foods other than formula were 
introduced before four months of age 
4. There was failure to complete one of the visits at 42, 119 or  
182 days, since these visits were regarded as essential
Although these subjects were withdrawn from the study for future 
analysis, they were still offered the study formula for the six-month 
period of the study. This also applied to infants who tested HIV 
positive.
In addition to anthropometric measurements at each visit, the 
infants were examined by the study personnel and a record was 
made of any illness and the concomitant treatments. The caregivers 
were interviewed at each visit regarding interim health status and 
the number of times the infant had been seen at any health-care 
facility since the last visit. In addition, a retrospective, two-day 
feeding questionnaire was completed at each visit. This included 
details of how much formula was prepared, how much remained in 
the bottle after each feed, and details of any other foods or liquids 
given in addition to the study formula. Furthermore, the mothers 
were instructed to return all unused formula at each visit and the 
returned amounts were correlated with the amounts that the infant 
was reported to have taken. A record of the stool pattern over 
the previous two days was collected in terms of stool frequency, 
colour and consistency. In addition, the frequency of spitting up 
and vomiting, and the infant’s behaviour with respect to “periods of 
unrest”, were recorded.
The study physicians collected blood specimens from a peripheral 
vein for all the infants on days 42, 119 and 182, where possible 
just before the next feed. On each of these occasions, blood was 
taken for the measurement of haemoglobin, albumin, total protein, 
blood urea, creatinine, quantitative amino acids, ferritin, C-reactive 
protein, calcium, sodium, phosphate, potassium, chloride and 
glucose. In addition, IgE (total and specific for a-lactalbumin, 
b-lactoglobulin, and total milk proteins) and IgG to hepatitis B 
surface protein (hepatitis B vaccine is given routinely in South 
Africa at six, 10 and 14 weeks of age) were assayed to assess 
immune status. Haemoglobin measurements were done by the 
local hospital laboratories and all the other assays were performed 
by the Centre Hospitalier Universitaire Vaudois, Laboratoire Central 
de Chimie Clinique in Lausanne, Switzerland. All specimens other 
than for haemoglobin measurement were collected in heparinised 
tubes, and put on ice until they were centrifuged within one hour 
of collection. The supernatant plasma was separated and then 
stored in a refrigerator at -70°C until it was shipped to Switzerland 
by a recognised international carrier. In addition to its use in the 
above tests, blood was collected on days 42 and 119 for HIV DNA 
polymerase chain reaction (PCR) tests, performed by the virology 
laboratory of the National Centre for Communicable Diseases 
in Johannesburg and by the virology laboratory of Groote Schuur 
Hospital in Cape Town. If there was a discrepancy between the two 
tests, a third test was done and, for further confirmation, one for viral 
load was done as well.  These results were regarded as definitive. 
All laboratories used in this study were subjected to internal and 
external quality control systems. 
The study was approved by the Committee for Research on Human 
Subjects of the University of the Witwatersrand and the University 
of Cape Town. All mothers of infants enrolled gave written informed 
consent. 
Due to the objective of the trial to demonstrate the safety of the 
acidified formulas, the sample size calculation was for a non-
inferiority study in HIV-exposed, uninfected infants concerning 
weight gain. The data collected by Nelson et al9 was used as a 
reference for the sample size calculation, with a mean gain in weight 
of 28 g/day (SD = 5.7) regarded as normal. A tolerance of 3.9 g/day 
between enrolment and four months of age was accepted as non-
inferior. A total number of 84 infants (28 per formulation group) were 
required to complete the study. On the basis of a previous study,10 it 
was initially estimated that a total of 120 infants would be sufficient 
for the required number of 84 HIV-uninfected infants to complete the 
study. However, allowing for those infected with HIV and those who 
did not complete the study, 150 (50 infants per formulation group) 
were ultimately recruited and randomised into the study.
The above calculation was based on the intention to show non-
inferiority in mean weight gain over four months in experimental 
versus control formulation groups. Non-inferiority was declared if 
the lower limit of a one-sided 95% confidence interval for the mean 
weight gain differences between the experimental and the control 
formulation group was entirely above the non-inferiority margin of 
-3.9 g/day. The above assumed a one-sided two-sample t-test, with 
a statistical power of 80% and an estimated standard deviation of 
5.7 g/day, based on data from Nelson et al.9 This power calculation 
was implemented using Power Analysis and Sample Size software 
(PASS, version 6.0).
An intention to treat (ITT) analysis, as well as a per protocol (PP) 
analysis, was planned. The growth parameters were calculated 
as mean growth velocities between 14 and 119 days of age (i.e. 
the time period for exclusive formula feeding). The effects of the 
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different dietary regimens were tested by analysis of variance 
(ANOVA) procedures controlling for gender. The Z-scores of the 
anthropometric parameters were calculated on the basis of the 2000 
Centers for Disease Control growth charts, and the Z-scores at the 
last visit (182 days) were compared using analysis of covariance 
(ANCOVA) correcting for the Z-scores at baseline. All statistical 
analyses were done using SAS software (version 8). A p-value of less 
than 0.05 was considered as significant.
Results
Enrolment commenced in September 2001 and the follow up 
of all infants was completed in December 2002. The baseline 
characteristics of the 150 infants enrolled can be seen in Table I. Of 
these, a total of 53 ‘dropped out’ during the course of the study and 
could not be traced, 25 of whom did so before the visit at six weeks 
of age. HIV status was available for 125 infants on the basis of at 
least one PCR test. Of these, 16 were HIV positive (12.8%). Of the 
109 infants who were HIV negative, a further 20 were lost to follow 
up, while five mothers fed their infants other milks or foods before 
four months of age. 
Those who were lost to follow up after six weeks were included in 
the intention-to-treat analysis, 37 of whom received the chemically 
acidified formula, 40 the acidified formula with prebiotics, and 32 
the acidified formula with prebiotics and nucleotides. A total of 
84 infants were eligible for the per-protocol analysis, 29 of whom 
received the chemically acidified formula, 32 the acidified formula 
with prebiotics, and 23 the acidified formula with prebiotics and 
nucleotides. These details are summarised in Figure 1.
The groups were comparable at enrolment with respect to birth 
data, anthropometric measurements, age and gender (Table I). The 
amount of formula consumed was not different during the course of 
the study. In the ITT analysis there were no statistically significant 
differences in average weight gain (g/day). Table II shows that the 
CAFP and CAFPN groups were not inferior to the CAF group, since 
the lower bounds of the 95% confidence interval are higher than the 
equivalence level of -3.9 g/day. Similar results were seen in the PP 
analysis, as shown in Table III.
At the last visit (182 days) there were no statistically significant 
differences in the weight Z-scores between the three formula 
groups (p  =  0.36 by ANCOVA, correcting for baseline Z-scores). 
Increases in length, head circumference and body mass index did 
not differ between the feeding groups, and at the last visit there was 
no difference in the length Z-score (p = 0.97), head circumference 
Z-score (p = 0.12) or weight-for-length Z-score (p = 0.25) between 
the three formula groups. Figure 2 shows the mean weight Z-scores 
for the three formula groups during the course of the study. The 
mean values at baseline were between -0.75 and -0.5, but the 
Table I: Demographic and anthropometric measurements at birth
Feeding group CAF CAFP CAFPN
Number of subjects 50 50 50
Sex
Male 23 22 22
Female 27 28 28
Birth weight (g) 3144 ± 401 3067 ± 364 3152 ± 426
Gestational age (wks) 39.3 ± 1.3 39.3 ± 1.4 39.5 ± 1.3
Vaginal delivery 33 (66%) 33 (66%) 34 (68%)
Antiretroviral treatment 50 (100%) 47 (94%) 48 (96%)
CAF: Chemically acidified formula
CAFP: Chemically acidified formula with prebiotics
CAFPN: Chemically acidified formula with prebiotics and nucleotides
HIV negative with 
full follow-up:
29
CAF: Chemically acidified formula
CAFP: Chemically acidified formula with prebiotics





































Figure 1: Flow diagram of participants
Table II: Comparison of weight gain between the 14-day and 119-day (four 
month) visit, as analysed on an intention-to-treat basis (Numbers in each 
group: CAF – 37, CAFP – 40, CAFPN – 32).
Intention-to-treat analysis (119- to 14-day visits)
Formulas  Mean (SE) One-sided 95%CI
CAFP vs CAF  2.34 (1.68) [-0.45; +∞]
CAFPN vs CAF  0.11 (1.77) [-2.82; +∞]
CAFPN vs CAFP  -2.40 (1.78)
Table III: Comparison of weight gain between the 14-day and 119-day 
(four-month) visit, as analysed in the per-protocol analysis (Numbers in 
each group: CAF – 29, CAFP – 32, CAFPN – 23).
Per-protocol analysis (119- to 14-day visits)
Formulas  Mean (SE) One-sided 95%CI
CAFP vs CAF  0.50 (1.65) [-2.24; +∞]
CAFPN vs CAF  -0.64(1.80 [-3.62; +∞]
CAFPN vs CAFP  -1.14 (1.76)
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scores increased over time and all groups had positive weight 
Z-scores by six weeks of age and were between +0.5 and +0.75 
by four months of age. Figure 3 shows a similar trend for the length 
Z-scores. Although the values did not increase as much as those for 
weight, they were in the positive range at the end of the study for all 
formula groups.
No statistically significant differences with respect to the frequency, 
consistency or colour of the stools were observed between the 
formula groups during the course of the study. The frequency of 
spitting, vomiting, flatulence and periods of unrest did not differ 
statistically between the groups. A total of 19 infants required 
admission to hospital during the course of the study (this figure 
included those testing HIV positive and/or those who were later 
withdrawn), three of whom required admission on two occasions. 
Of these, nine were in the CAF group, seven in the CAFP group and 
three in the CAFPN group (differences not significant). Nineteen of 
these admissions were for either lower respiratory tract infections 
or gastroenteritis, while the other three were for miscellaneous 
conditions. One infant in the CAFP group died during the course of 
the study, from gastroenteritis, septicaemia and herbal medicine 
ingestion on day 39 of the study, prior to an HIV test being done.
No statistically significant differences were noted between the 
formula groups with respect to haemoglobin or any of the biochemical 
measures performed, and no significant abnormalities were noted 
in any of the groups. With respect to the amino acid analyses, the 
only differences noted were that aspartate levels were significantly 
lower in the CAFPN group, while glycine levels were significantly 
lower in the CAF group. Levels of specific IgE were generally below 
the detection limit (0.35 kU/l) and therefore were not analysed 
statistically. Total IgE levels increased with age, but there were no 
differences in mean levels between the groups. Similarly, hepatitis 
B antibody titres increased with age, as expected as a result of the 
immunisation programme, but no differences were noted between 
the groups.
Discussion
The study corresponded with the time of significant expansion of 
the government MTCT programme, but the expanded programme 
developed much more rapidly in the urban centres. As a result, many 
pregnant women were coming to the urban centres for the benefits 
of the MTCT programme, giving local addresses and, in a number 
of cases, enrolling their infants in the study but returning to their 
rural homes within a few weeks. Thus, although more infants than 
originally expected failed to complete the study, this was not thought 
to be related to any problems experienced with the study formulas. 
However, although there is no reason to suspect that those who were 
lost to follow up and those who completed the study differed in any 
way, this is a potential pitfall in the interpretation of the results. There 
were no differences in the numbers of infants who were lost to follow 
between the three feeding groups, and the smaller number of HIV-
uninfected infants who completed the study in the CAFPN group was 
mainly as a result of a trend (not statistically significant) towards a 
larger number of infants becoming HIV infected in that group – an 
event unrelated to the study formulas.
Both the ITT and the PP analysis showed no differences with 
respect to growth, and the formulas containing prebiotics with or 
without nucleotides were not inferior to those without probiotics 
or nucleotides. This was expected, as neither prebiotics nor 
nucleotides have previously been shown to enhance growth. What 
was noteworthy was that the mean Z-scores were below the means 
of the NCHS norms at the time of enrolment in the study, but that 
they increased during the course of the study, and the mean weight 
Z-scores were greater than 0.5 for weight by four months of age and 
the length Z-scores had become positive by the end of the study. 
In a previous birth cohort study in Johannesburg during the early 
1990s, improvements in weight and length Z-scores were noted 
in the first six months of life.11 However, in that study the Z-score 
was 0.02 for weight and -0.54 for length at six months of age – 
substantially lower than the scores seen in this study. It is likely that 
the free supply of milk for this group of infants from poor socio-
economic circumstances, the careful and continuous monitoring of 
their growth and the fact that infants who developed serious illness 
generally did not complete the study were all factors responsible for 
the greater gains in weight and length seen in this study. 
From a study on premature infants, conducted by Ballabriga et al12 
several decades ago and utilising chemically acidified formulas, 
it was concluded on safety grounds that only L(+) lactic acid 
Figure 2: Weight for age Z-scores during the course of the study for the 
three feeding groups
Figure 3: Length for age Z-scores during the course of the study for the 
three feeding groups
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should be used for the chemical acidification of infant formulas, 
since the infants who received the D form developed a significant 
metabolic acidosis. Unlike the L form, which is rapidly metabolised, 
the D form may accumulate in the body, resulting in a significant 
acidosis.13 Since then, the literature on acidified infant formulas has 
concentrated on formulas that are biologically acidified with lactic 
acid-producing bacteria during the production process. This is one of 
the first studies on normal-term infants utilising chemically acidified 
formulas. Growth and tolerance of the formula were equivalent to 
the findings of a previous study in which we utilised a standard, 
non-acidified formula and one that was biologically acidified.10 Thus, 
the chemical acidification of a starter infant formula appears to be a 
realistic alternative to biological acidification and may have benefits 
with respect to cost and consistency, as discussed previously. 
Although the acid base status of the infants in this study was not 
measured systematically, some random venous blood gases were 
performed and all were normal. The effects of both biologically 
and chemically acidified formulas on the acid base balance were 
addressed systematically in a separate study conducted by our 
group and shown to be safe.14
With respect to the differences seen in the amino acid profiles, it 
should be noted that many parameters were tested and no correction 
for multiple testing, such as the Bonferroni test, was done. It is 
probable that these differences were chance findings and that they 
have no clinical significance.
A number of studies have shown beneficial effects of both prebiotics 
and nucleotides when added to infant formulas. Prebiotics have 
been shown to alter the balance of the gut microbiota, with 
potentially protective effects against diarrhoea and other infective 
illnesses,15,16,17 while a recent study showed a reduction in atopic 
dermatitis during the first six months of life in the group receiving 
a formula with prebiotics.18 Nucleotide supplementation has been 
shown to increase the antibody response to certain immunisations 
given in infancy, and to reduce episodes of diarrhoea.6,7,19 Our study 
was unable to show any of these effects for either the prebiotics 
or nucleotides utilised in this study. However, since our study was 
powered to assess growth and not any of these end points, it was 
probably underpowered to show any such benefits.
With respect to the safety of the formulas, we could find no evidence 
to suggest any concerns regarding chemical acidification or the 
addition of prebiotics and/or nucleotides.
Conclusions 
All three chemically acidified formulas used in this study were 
tolerated well. No differences in growth parameters were seen 
with the addition of prebiotics and nucleotides, and all three groups 
showed satisfactory growth rates compared with those we have 
studied on standard formulas.10,14 Chemical acidification of formulas 
for healthy term infants did not give rise to any safety concerns 
in this study and, given the potential cost benefits, such formulas 
deserve further study. 
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